COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 2 of 731 for:    young plasma

Study to Explore the Safety and Feasibility of Allogeneic Young Plasma Infusion in Older Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04241159
Recruitment Status : Withdrawn (Protocol required revisions and application was withdrawn from the IRB.)
First Posted : January 27, 2020
Last Update Posted : May 22, 2020
Information provided by (Responsible Party):
Wake Forest University Health Sciences

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : August 2020
Estimated Study Completion Date : August 2020
Aging Well in the 21st Century: Strategic Directions for Research on Aging. [cited 2018 8/10/18]; Available from:
Bilder, G., Human biological aging : from macromolecules to organ-systems. 2016, Hoboken, New Jersey: Wiley Blackwell. ix, 330 pages.
Savarese, D. Common Terminology Criteria for Adverse Events. 2019 [cited 2019 2019]; Available from:
Silvergleid, A.J. Clinical Use of Plasma Components. [cited 2019]/ Available from:
The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study (PLASMA). Available from:
Reversing Epigenetic & Other Markers of Senescence by Transfusing Young Plasma To Older Human Subjects (RESET-YOUTH). Available from:
Fresh Frozen Plasma: Indications and Risks: NIH Consensus Development Conference Statement. 1984 9/11/2018]; Available from:
Silvergleid, A.J. Approach to the patient with a suspected acute transfusion reaction. 4/23/18]; Available from:
Diane, S. Common Terminology Criteria for Adverse Events. April 23, 2018; Available from: